Compare Stocks: SGEN, VRTX, REGN, and ARGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$1,001.62 +1.8%	$934.10	$661.85 ▼ $1,072.75	$62.75B	0.47	337,791 shs	47,969 shs
REGN Regeneron Pharmaceuticals	$785.74 +0.5%	$754.93	$541.00 ▼ $859.34	$81.01B	0.2	826,869 shs	95,967 shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	N/A
VRTX Vertex Pharmaceuticals	$518.43 +0.6%	$511.01	$374.17 ▼ $560.25	$131.59B	0.32	1.40 million shs	141,808 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-4.72%	+15.64%	+11.33%	+30.14%
REGN Regeneron Pharmaceuticals	0.00%	-5.59%	-2.74%	+27.08%	+39.55%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%
VRTX Vertex Pharmaceuticals	0.00%	-5.62%	+1.92%	+14.43%	+30.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$1,001.62 +1.8%	$934.10	$661.85 ▼ $1,072.75	$62.75B	0.47	337,791 shs	47,969 shs
REGN Regeneron Pharmaceuticals	$785.74 +0.5%	$754.93	$541.00 ▼ $859.34	$81.01B	0.2	826,869 shs	95,967 shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	N/A
VRTX Vertex Pharmaceuticals	$518.43 +0.6%	$511.01	$374.17 ▼ $560.25	$131.59B	0.32	1.40 million shs	141,808 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-4.72%	+15.64%	+11.33%	+30.14%
REGN Regeneron Pharmaceuticals	0.00%	-5.59%	-2.74%	+27.08%	+39.55%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%
VRTX Vertex Pharmaceuticals	0.00%	-5.62%	+1.92%	+14.43%	+30.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.88	Moderate Buy	$1,158.61	15.67% Upside
REGN Regeneron Pharmaceuticals	2.58	Moderate Buy	$802.18	2.09% Upside
SGEN Seagen	0.00	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	2.96	Moderate Buy	$570.83	10.11% Upside

Current Analyst Ratings Breakdown

Latest SGEN, VRTX, REGN, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	VRTX Vertex Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$515.00 ➝ $560.00
9/10/2026	VRTX Vertex Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/10/2026	REGN Regeneron Pharmaceuticals	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$800.00 ➝ $920.00
9/3/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,150.00
9/1/2026	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$665.00
9/1/2026	VRTX Vertex Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$653.00
8/31/2026	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,230.00 ➝ $1,250.00
8/26/2026	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,350.00 ➝ $1,415.00
8/26/2026	ARGX argenex	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$960.00 ➝ $1,400.00
8/25/2026	VRTX Vertex Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/24/2026	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	14.75	$21.70 per share	46.15	$118.34 per share	8.46
REGN Regeneron Pharmaceuticals	$14.34B	5.64	$42.20 per share	18.62	$295.66 per share	2.66
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15
VRTX Vertex Pharmaceuticals	$12.00B	10.96	$17.68 per share	29.33	$73.57 per share	7.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	38.52	26.87	1.02	32.19%	43.59%	36.66%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	19.45	15.55	1.53	27.86%	13.47%	10.34%	10/28/2026 (Estimated)
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A
VRTX Vertex Pharmaceuticals	$3.95B	$17.18	30.18	28.14	2.24	35.00%	23.09%	16.72%	11/2/2026 (Estimated)

Latest SGEN, VRTX, REGN, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026	VRTX Vertex Pharmaceuticals	$4.74	$4.73	-$0.01	$4.31	$3.23 billion	$3.33 billion
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.48%	N/A	9.29%	N/A
SGEN Seagen	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest SGEN, VRTX, REGN, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
SGEN Seagen	N/A	2.67	2.12
VRTX Vertex Pharmaceuticals	N/A	3.19	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
REGN Regeneron Pharmaceuticals	83.31%
SGEN Seagen	84.26%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
REGN Regeneron Pharmaceuticals	6.97%
SGEN Seagen	25.90%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	No Data
VRTX Vertex Pharmaceuticals	6,400	253.80 million	253.30 million	Optionable

SGEN, VRTX, REGN, and ARGX Headlines

Recent News About These Companies

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

17 minutes ago | seekingalpha.com

Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead

3 hours ago | marketbeat.com

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

4 hours ago | fool.com

Corient Private Wealth LP Acquires 17,263 Shares of Vertex Pharmaceuticals Incorporated $VRTX

September 13 at 3:52 AM | marketbeat.com

JPMorgan Chase & Co. Reaffirms Overweight Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)

September 13 at 1:43 AM | americanbankingnews.com

Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis

September 12 at 7:00 AM | marketbeat.com

Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference

September 12 at 6:00 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Allworth Financial LP

September 12 at 3:44 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

September 11 at 6:17 PM | finance.yahoo.com

Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis

September 11 at 6:11 PM | insidermonkey.com

Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher

September 11 at 1:17 PM | finance.yahoo.com

JPMorgan Chase & Co. Reaffirms "Overweight" Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)

September 11 at 8:41 AM | marketbeat.com

Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher

September 11 at 8:03 AM | fxempire.comF

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 10, 2026 | finance.yahoo.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Q2 rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) vs other therapeutics stocks

September 10, 2026 | msn.com

Tidal Investments LLC Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

September 10, 2026 | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by National Pension Service

September 10, 2026 | marketbeat.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution

September 9, 2026 | seekingalpha.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by HighTower Advisors LLC

September 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGEN, VRTX, REGN, and ARGX Company Descriptions

argenex NASDAQ:ARGX

$1,001.62 +17.23 (+1.75%)

As of 11:18 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Regeneron Pharmaceuticals NASDAQ:REGN

$785.74 +4.25 (+0.54%)

As of 11:18 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Vertex Pharmaceuticals NASDAQ:VRTX

$518.43 +2.99 (+0.58%)

As of 11:18 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGEN, VRTX, REGN, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGEN, VRTX, REGN, and ARGX Earnings

Compare Dividends

Latest SGEN, VRTX, REGN, and ARGX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGEN, VRTX, REGN, and ARGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGEN, VRTX, REGN, and ARGX Company Descriptions

argenex NASDAQ:ARGX

Regeneron Pharmaceuticals NASDAQ:REGN

Seagen NASDAQ:SGEN

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SGEN, VRTX, REGN, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SGEN, VRTX, REGN, and ARGX Earnings

Compare Dividends

Latest SGEN, VRTX, REGN, and ARGX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SGEN, VRTX, REGN, and ARGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGEN, VRTX, REGN, and ARGX Company Descriptions

argenex NASDAQ:ARGX

Regeneron Pharmaceuticals NASDAQ:REGN

Seagen NASDAQ:SGEN

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools